摘要
目的 探讨IL-17、IL-35在甲状腺癌患者血清中的表达及临床意义。方法 回顾性分析2012年7月~2015年7月我院住院治疗的88例甲状腺疾病患者的临床资料,55例为甲状腺癌,33例为甲状腺腺瘤,另外选择同期于我院进行体检的健康者40例作为对照组。采用ELISA法测定血清中IL-17及IL-35水平。比较各组血清IL-17及IL-35水平、不同类型甲状腺癌患者血清中IL-17及IL-35水平。结果 （1）甲状腺腺瘤与对照组血清IL-17及IL-35水平差异均无统计学意义（P〉0.05）,甲状腺癌患者血清中IL-17及IL-35水平与甲状腺腺瘤组及对照组比较差异有统计学意义（P〈0.01）;（2）血清中IL-17水平比较,AB〉C,两两之间差异具有统计学意义（P〈0.01）。结论 IL-17、IL-35参与甲状腺癌的发生、发展过程,可以作为临床治疗及诊断、预后评估的参考指标之一。
Objective To investigate the expression and clinical significance of serum IL-17, IL-35 in thyroid cancer patients. Methods A retrospective analysis of the 88 cases of thyroid disease patients in our hospital from July 2012 to July 2015, 55 cases of thyroid cancer, 33 cases of thyroid cancer, chose another 40 cases health examination as the control group. The serum IL-17 and IL-35 levels were checked by ELISA. The serum IL-17 and IL-35 levels in three groups and different types of thyroid cancer were compared. Results （1）The serum levels of IL-17 and IL-35 levels were not significantly different in thyroid tumor and control group （P〉0.05）, IL-17 and IL-35 in serum thyroid cancer patients were significantly different with those in thyroid adenoma and the control group （P〈0.01）; （2）For serum IL-17 level, the papillary thyroid carcinoma〈follicular thyroid carcinoma〈anaplastic thyroid cancer, with significant statistical significance among them（P〈0.01）; the serum IL-35 level, the papillary thyroid carcinoma〉follicular thyroid carcinoma〉 anaplastic thyroid cancer, with significant statistical significance among them. Conclusion IL-17 and IL-35 participate in the occurrence and development of thyroid cancer, can be used as a reference index for clinical treatment and diag- nosis and prognosis evaluation.
出处
《中国现代医生》
2016年第15期99-101,共3页
China Modern Doctor
